BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Neurology

...antagonist VA111913 in Phase II testing to treat dysmenorrhea. Azevan Pharmaceuticals Inc.'s V1a receptor antagonist, SRX251...
BioCentury | Nov 17, 2008
Emerging Company Profile

Vantia: New irons in the fire

...precedent for the approach. At least one other V1a receptor antagonist is in the clinic: SRX251...
Items per page:
1 - 2 of 2